Get started
Author

Françoise Boyer

Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs
2012 · Robyn M. Emanuel, Amylou C. Dueck, et al. · Journal of Clinical Oncology · 458
PDF
Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study
2021 · Damien Luque Paz, Jérémie Riou, et al. · Blood Advances · 80
Leukemic evolution of polycythemia vera and essential thrombocythemia: genomic profiles predict time to transformation
2020 · Damien Luque Paz, Rébecca Jouanneau-Courville, et al. · Blood Advances · 77
PDF
Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group
2016 · Holly L. Geyer, Heidi Kosiorek, et al. · Haematologica · 77
PDF
Practical application and clinical impact of the WHO histopathological criteria on bone marrow biopsy for the diagnosis of essential thrombocythemia versus prefibrotic primary myelofibrosis
2010 · Maud Brousseau, Elsa Parot‐Schinkel, et al. · Histopathology · 75
PEG‐IFN‐α‐2a therapy in patients with myelofibrosis
2009 · Jean‐Christophe Ianotto, Jean‐Jacques Kiladjian, et al. · British Journal of Haematology · 66
Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease
2015 · Holly Geyer, Robyn Scherber, et al. · Journal of Clinical Oncology · 65
Ruxolitinib Before Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) In Patients With myelofibrosis : a Preliminary Descriptive Report Of The JAK ALLO Study, a Phase II Trial Sponsored By Goelams-FIM In Collaboration With The Sfgmtc
2013 · Marie Robin, Sylvie Francois, et al. · Blood · 64
Thalidomide versus placebo in myeloid metaplasia with myelofibrosis: a prospective, randomized, double-blind, multicenter study.
2006 · Jean-François Abgrall, Isabelle Guibaud, et al. · PubMed · 47
Clinical and biological characterization of MPN patients harboring two driver mutations, a F rench intergroup of myeloproliferative neoplasms (FIM) study
2017 · Olivier Mansier, Damien Luque Paz, et al. · American Journal of Hematology · 41
PDF
Ruxolitinib before allogeneic hematopoietic transplantation in patients with myelofibrosis on behalf SFGM-TC and FIM groups
2021 · Marie Robin, Raphael Porcher, et al. · Bone Marrow Transplantation · 34
PDF
Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs
2017 · Allison H. Scotch, Heidi Kosiorek, et al. · Leukemia Research · 28
Sequential analysis of 18 genes in polycythemia vera and essential thrombocythemia reveals an association between mutational status and clinical outcome
2016 · Damien Luque Paz, Aurélie Chauveau, et al. · Genes Chromosomes and Cancer · 20
Long-term follow-up of JAK2 exon 12 polycythemia vera: a French Intergroup of Myeloproliferative Neoplasms (FIM) study
2020 · Sylvie Tondeur, Franciane Paul, et al. · Leukemia · 19
Flow cytometry-evaluated platelet CD36 expression, reticulated platelets and platelet microparticles in essential thrombocythaemia and secondary thrombocytosis
2010 · Marie-Pierre Moles-Moreau, Catherine Ternisien, et al. · Thrombosis Research · 17
Histological and genetic characterization and follow-up of 130 patients with chronic triple-negative thrombocytosis
2022 · Sandrine Lemoine, Clelia Mornet, et al. · Haematologica · 16
PDF
Sequential mutational evaluation of CALR ‐mutated myeloproliferative neoplasms with thrombocytosis reveals an association between CALR allele burden evolution and disease progression
2019 · Laurane Cottin, Jérémie Riou, et al. · British Journal of Haematology · 15
PDF
Myeloproliferative (MPN) Symptom Burden Response Thresholds: Assessment Of MPN-SAF TSS Quartiles As Potential Markers Of Symptom Response
2013 · Robyn M. Emanuel, Amylou Constance Dueck, et al. · Blood · 13
Efficacy and safety of ruxolitinib in patients with myelofibrosis and low platelet count (50 × 10 9 /L to <100 × 10 9 /L) at baseline: the final analysis of EXPAND
2022 · Paola Guglielmelli, Jean-Jacques Kiladjian, et al. · Therapeutic Advances in Hematology · 12
PDF
Transfusion-Transmitted Hepatitis A Virus, France, 2018
2021 · Caroline Lefeuvre, Caroline Lefort, et al. · Emerging infectious diseases · 12
PDF
S210: an Open-label, Global, Phase (ph) 1b/2 Study Adding Navtemadlin (nvtm) to Ruxolitinib (rux) in Patients (pts) With Primary or Secondary Myelofibrosis (mf) Who Have a Suboptimal Response to Rux
2023 · John Mascarenhas, Tania Jain, et al. · HemaSphere · 11
WT1 gene is overexpressed in myeloproliferative neoplasms, especially in myelofibrosis
2018 · Laurane Cottin, Jérémie Riou, et al. · Blood Cells Molecules and Diseases · 10
PDF
Insomnia, Quality Of Life and MPN Symptom Burden: An Analysis By The MPN Quality Of Life International Study Group (MPN-QOL ISG)
2013 · Holly Lynn Geyer, Amylou Constance Dueck, et al. · Blood · 10
Sexuality Challenges, Intimacy, and MPN Symptom Burden: An Analysis By The MPN Quality Of Life International Study Group (MPN-QOL ISG)
2013 · Holly Lynn Geyer, Amylou C. Dueck, et al. · Blood · 8
Phase 1/2 Study of the Activin Receptor-like Kinase-2 Inhibitor Zilurgisertib (INCB000928, LIMBER-104) As Monotherapy or with Ruxolitinib in Patients with Anemia Due to Myelofibrosis
2023 · Sanjay Mohan, Stephen Oh, et al. · Blood · 7
Works count: 72
Citation count: 1,357
H-index: 16
I10-index: 23
Year
Topic
Type